Medical technology manufacturer ZETA SURGICAL and HOPE Therapeutics, an NRx Pharmaceuticals company (Nasdaq:NRXP), announced on Tuesday that the first patient has been treated with the FDA-cleared Zeta TMS Navigation System at a HOPE Therapeutics clinic in Sarasota.

HOPE has installed Zeta TMS Navigation Systems at clinics in West Palm Beach and Sarasota, with Zeta-navigated patient treatments beginning at both locations this week.

TMS is a non-invasive therapy used primarily for treatment-resistant depression, which affects approximately one-third of patients with major depressive disorder. TMS is also used in other neuropsychiatric conditions, including obsessive-compulsive disorder and other disorders involving brain circuit dysfunction.

The Zeta TMS Navigation System uses proprietary RealTrack technology to provide real-time, markerless image guidance for TMS procedures. The system applies artificial intelligence and computer vision to register a patient's MRI or CT imaging to their facial anatomy in under two minutes and continuously track the position of the TMS coil relative to the planned brain target with sub-millimetric accuracy. At HOPE, the system has been incorporated into outpatient TMS workflows for eligible patients, including those receiving treatment for major depressive disorder.